Skip to NavigationSkip to content

Chiltern acquires Ockham to help lift status

Published on 16/07/14 at 07:28am

Chiltern has today acquired a full stake in fellow contract research organisation Ockham as both companies look to merge their operations.

The combined company will be called simply ‘Chiltern’, whilst Ockham’s senior team will join the management of the enlarged group.

Chiltern’s chief executive Jim Esinhart will become the new boss of the Chiltern Group, with Ockham’s chief executive James Baker becoming chief development officer. Nick Thornton will remain as chairman.

This complementary transaction aims to strengthen the combined service offerings in three strategic areas, namely:

· Oncology specialisation with a focus across all clinical phases of development (known as Chiltern Oncology)

· Biopharmaceutical services, including respiratory, ophthalmology, infectious disease, vaccines and dermatology (known as Chiltern Biopharmaceutics)

· Global Functional Service Provider (FSP)/sourcing provision specialising in tailored resourcing solutions across clinical, regulatory, medical and biometrics (known as Chiltern Source).

Esinhart says: “This merger is a natural progression towards our strategic goal of becoming the premier specialised mid-tier CRO. Throughout this process I have been extremely impressed by the skill and professionalism of Ockham’s employees, the quality services they deliver, and the vision of the leadership team.

“There is a perfect strategic fit between our companies and I’m excited to work with the entire Ockham team to ensure a seamless continuation in the delivery of high quality services to all of the combined company’s clients.”

Baker adds: “In Ockham’s continuing progression toward building the top niche oncology CRO, our joining with Chiltern has been an easy choice, allowing us to leverage Chiltern’s global reach and highly developed staffing business in Europe, both of which are complementary to Ockham’s deep oncology expertise and source business in the US.

“We are fortunate to have found the ideal partner with a complete understanding and commitment to the unique needs of our emerging biotech clientele.”

Ben Adams


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches